← Back to all trials
Not Yet Recruiting
NCT07734012
Mycophenolate After Stem Cell Transplant for Systemic Sclerosis
Conditions: Systemic Sclerosis (SSc)
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 6
Sponsor: Ottawa Hospital Research Institute
Location: The Ottawa Hospital Ottawa Ontario
Summary
A pilot single center randomized trial to test whether a full-scale RCT evaluating the role of post-AHSCT maintenance immunosuppression with MMF in preventing disease relapse is feasible .
We are studying whether a brief course of treatment with MMF after AHSCT will serve to prevent disease relapse.
Eligibility Criteria
Inclusion Criteria:
* Consenting participants 18 years of age or older who are initiating AHSCT at The Ottawa Hospital for management of SSc.
Exclusion Criteria:
* Exclusion criteria are focused on patient safety, namely inability to receive treatment with
MMF due to contraindications as determine at time of randomization (day 90 / clinic visit #3) including:
* Renal insufficiency (eGFR \
Source: ClinicalTrials.gov (NCT07734012). StuddyBuddy aggregates publicly available trial information.
